<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00828620</url>
  </required_header>
  <id_info>
    <org_study_id>s51276 - ML5241</org_study_id>
    <nct_id>NCT00828620</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project</brief_title>
  <official_title>Imaging for Early Response Prediction to EGF-receptor Blocking Monoclonal Antibodies in Combination Therapy for Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Molecular imaging with positron emission tomography (PET) using [18F] fluorodeoxyglucose
      (FDG) has been suggested as an early, sensitive marker of tumour response to anticancer drugs
      by monitoring the changes in glucose metabolism in tumours. Recently, FDG-PET has shown to be
      highly sensitive in detecting early response in other tumours. In this study, the
      investigators will prospectively investigate the role of early FDG-PET (at day 7 and week 6)
      in outcome prediction.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of recruitment
  </why_stopped>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>PET response on day 7</measure>
    <time_frame>day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine whether the PET criteria for response on day 7 correlates with the CT criteria of minimum 10% decrease in tumour size (RECIST) at week 6</measure>
    <time_frame>week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To define the optimal cutoff value of SUVmax and their predictive value</measure>
    <time_frame>at day 7 and week 6</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To explore the test/retest reliability of PET/CT in this setting</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the value of PET/CT at day 7 in predicting overall survival</measure>
    <time_frame>up to 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To asses the correlations between biomarkers and PET changes after Cetuximab</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">21</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>PET-CT</arm_group_label>
    <description>Patients with Unresectable stage IV colorectal cancer; eligible for 3rd line Irinotecan and Cetuximab</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Imaging study</intervention_name>
    <description>PET-CT</description>
    <arm_group_label>PET-CT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        unresectable stage IV colorectal cancer pathologically proven measurable disease (RECIST)
        K-RAS wild type Eligible for 3rd line Irinotecan + Cetuximab Able for tolerate PET/CT
        imaging Serum glucose &lt; 200mg/dl
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically proven colorectal cancer

          -  Unresectable stage IV disease

          -  K-Ras wild type tumour

          -  Patients scheduled to undergo chemotherapy with irinotecan and cetuximab

        Exclusion Criteria:

          -  Prior abdominal/pelvic radiotherapy, surgery or chemotherapy within 3 months prior to
             inclusion in the study

          -  Poorly controlled diabetes

          -  Concomitant serious illness, such as uncontrolled angina pectoris, myocardial
             infarction, heart failure, uncontrolled hypertension, infection

          -  Symptomatic brain metastases

          -  Pregnancy or participants of reproductive potential who are sexually active and not
             willing/able to use medically appropriate contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Van Cutsem, Prof.Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ZNA Middelheim</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Groeninge</name>
      <address>
        <city>Kortrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZLeuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H Hart Roeselare Campus menen</name>
      <address>
        <city>Menen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stedelijk Ziekenhuis Roeselare</name>
      <address>
        <city>Roeselare</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sint Augustinus Ziekenhuis</name>
      <address>
        <city>Wilrijk</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2009</study_first_submitted>
  <study_first_submitted_qc>January 23, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2009</study_first_posted>
  <last_update_submitted>August 9, 2012</last_update_submitted>
  <last_update_submitted_qc>August 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

